We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. (PANTAX-Ib)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04652206
Recruitment Status : Recruiting
First Posted : December 3, 2020
Last Update Posted : December 29, 2021
Sponsor:
Collaborator:
Alcedis GmbH
Information provided by (Responsible Party):
Scandion Oncology A/S

Tracking Information
First Submitted Date  ICMJE November 20, 2020
First Posted Date  ICMJE December 3, 2020
Last Update Posted Date December 29, 2021
Actual Study Start Date  ICMJE October 27, 2020
Estimated Primary Completion Date March 30, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 26, 2020)
  • Safety and Tolerability [ Time Frame: Through study completion, assessed up to 100 months ]
    Safety and tolerability by assessing the number, frequency, and severity of adverse events (AEs) collected from the time of first treatment until four weeks after end of treatment to evaluate safety of SCO-101 in combination with gemcitabine and nab-paclitaxel determined according to the Common Terminology Criteria for Adverse Events (NCI-CTCAE v.5.0).
  • Maximum Tolerated Dose [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
    To determine the Maximum Tolerated Dose (MTD) of SCO-101 in combination with gemcitabine and nab-Paclitaxel by assessment of Dose Limiting Toxicities (DLT) to SCO-101.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 26, 2020)
  • Objective Response Rate [ Time Frame: Tumor assessment is performed every two treatment cycles (2 months), assessed up to 100 months. ]
    defined as CR and PR using the RECIST v. 1.1
  • Clinical Benefit Rate (CBR) [ Time Frame: From benefit (CR, PR or SD > 16 weeks) to progression, assessed up to 100 months ]
    defined as the number of patients obtaining CR, PR, or SD > 16 weeks according to RECIST v.1.1.
  • Progression Free Survival (PFS) [ Time Frame: From first dosing to progression, assessed up to 100 months ]
    defined as time in months from the date of first study treatment with SCO-101 to the date of disease progression or death from any cause, whichever comes first.
  • Overall Survival [ Time Frame: through study completion, assessed up to 100 months ]
    defined as time in months from the date of first study treatment to the date of death
  • Pharmacokinetic profile [ Time Frame: during the first 14 treatment days in the first treatment cycle. ]
    Pharmacokinetic profile of SCO-101 alone and in combination with gemcitabine and nab-paclitaxel
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: November 26, 2020)
Novel predictive biomarker feasibility [ Time Frame: assessed from first administration to end of treatment, assessed up to 100 months. ]
assessment of biomarkers from blood and tumor
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
Official Title  ICMJE An Open-label Phase Ib Prospective Clinical Trial to Investigate Safety, Tolerability and Maximum Tolerated Dose for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
Brief Summary An open-label dose escalating phase Ib study of SCO-101 in combination with gemcitabine and nab-paclitaxel. The primary objectives are to establish the safety profile and the MTD of SCO-101 when combined with gemcitabine and nab-paclitaxel. The starting dose of SCO-101 is 150 mg and the dose may be increased to a maximum of 350 mg.
Detailed Description The study is an open-label dose escalating phase Ib study of SCO-101 in combination with gemcitabine and nab-paclitaxel. The primary objective is to establish the safety, tolerability and MTD of SCO-101 when combined with gemcitabine and nab-paclitaxel. Secondary objectives are efficacy and to establish PK parameters of SCO-101. The target indication is patients with inoperal pancreatic cancer who are to be treated with gemcitabine and nab-paclitaxel. The study is designed as a standard 3+3 dose escalation study with increasing doses of SCO-101 and a fixed dose (standard regimen) of gemcitabine and nab-paclitaxel. An interim report will be prepared once the last patient in the MTD cohort has completed one treatment cycle. Patients will continue treatment until disease progression to evaluate secondary objectives. One treatment Cycle is 28 days. The starting dose of SCO-101 is 150 mg 6 daily dosing in a bi-weekly schedule) and may be increased to a maximum of 350 mg (5 cohorts with 50 mg increments). A total of up to 18 patients are anticipated if dose escalation to the 5th cohort. Gemcitabine and nab-paclitaxel is administered according to local standard recommendations once weekly for three weeks followed by one weeks treatment holiday (dosing on day 6, day 13 and day 20). Patients may continue treatment until treatment progression.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
Standard 3+3 dose escalation design to determine the Maximum Tolerated dose (MTD) of SCO-101 when administered in combination with gemcitabine and nab-paclitaxel, in patients with inoperable pancreatic cancer
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Metastatic Pancreatic Adenocarcinoma
  • Locally Advanced Pancreatic Adenocarcinoma
  • Inoperable Disease
  • Localized Pancreatic Adenocarcinoma
Intervention  ICMJE
  • Drug: SCO-101
    Oral tablets with a strength of 50 mg or 150 mg according to dose level (cohort). Administered for 6 consequtive days in a bi-weekly schedule in each treatment cycle. Treatment until disease progression.
  • Drug: Gemcitabine
    Used according to marketing authorisation
  • Drug: Nab paclitaxel
    Used according to marketing authorisation
Study Arms  ICMJE Experimental: SCO-101 in combination with gemcitabine and nab-paclitaxel

Patients receive escalating doses of SCO-101 in combination with the standard recommended dose of gemcitabine and nab-paclitaxel according to local clinical practice. Gemcintabine and nab-paclitaxel is the recommended treatment for the patient group.

Starting dose of SCO-101 is 150 mg. Maximum dose tested is 350 mg. The dose is increased with 50 mg increments between each cohort.

Interventions:
  • Drug: SCO-101
  • Drug: Gemcitabine
  • Drug: Nab paclitaxel
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: November 26, 2020)
18
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 15, 2022
Estimated Primary Completion Date March 30, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Patients are required to meet all of the following criteria for enrollment into the study:

  1. Ability to understand and willingness to provide written informed consent before any trial-related activities.
  2. Age 18 years or older.
  3. Histologically or cytologically verified pancreatic adenocarcinoma.
  4. Inoperable localized, locally advanced or metastatic pancreatic cancer, not amenable for curatively intended treatment, in patients who are to be treated with gemcitabine and nab-paclitaxel.
  5. Measurable or non-measurable disease determined by CT scan or MRI, according to RECIST 1.1.
  6. Performance status of ECOG ≤ 2 and expected to tolerate the standard recommended (100%) gemcitabine and nab-paclitaxel dose.
  7. Recovered to Grade 1 or less from prior surgery or acute toxicities of prior radiotherapy or treatment with cytotoxic or biologic agents.
  8. ≥ 2 weeks must have elapsed since any prior surgery or radiotherapy.
  9. Adequate conditions as evidenced by the following clinical laboratory values:

    • Absolute neutrophils count (ANC) ≥ 1.5 x 109/L
    • Haemoglobin ≥ 6.0 mmol/L
    • Platelets ≥ 100 x 109 /L
    • Alanine aminotransferase (ALT) ≤ 2.5 x ULN and aspartate aminotransferase (AST) ≤ 2.5 x ULN*
    • Total Serum bilirubin ≤ 1.0 ULN
    • Alkaline phosphatase ≤ 2.5 x ULN*
    • Creatinine ≤ 1.5 ULN
    • eGFR within normal limits
    • Adequate blood clothing function as defined by the International Normalized Ratio (INR) ≤ 1.2
  10. Life expectancy longer than 3 months.
  11. Sexually active males and females of child-producing potential must use highly effective contraception (intrauterine devices, hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release)) for the study duration and at least 6 months after the last dose of study drug.
  12. Signed informed consent. *AST is not mandatory. In case of known liver metastases with ALT and AST ≤ 5 x ULN and/or alkaline phosphatase ≤ 5 x ULN: Patients who do not conform to the transaminase and/or alkaline phosphatase inclusion criteria, but who by the PI are considered in good PS and otherwise eligible for inclusion, and where the transaminase and/or alkaline phosphatase levels are considered elevated due to other reasons than deteriorated lever capacity, may be considered for inclusion based on conferred agreement between PI and sponsor.

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded from enrollment:

  1. Concurrent chemotherapy, radiotherapy, or other investigational drug during study period.
  2. Previous surgeries with resection of the complete stomach or greater part of small intestines (excluding the duodenum), whereby absorption of SCO-101 may be affected. Treatment with Creon or similar is allowed.
  3. Difficulty in swallowing tablets.
  4. CNS metastases requiring steroids.
  5. Treatment with antibiotics for infections or with clinical symptoms of active infection. Patients showing symptoms of CoViD19 must be tested for active CoViD19 infection.
  6. Known HIV positivity.
  7. Known active hepatitis B or C.
  8. Clinically significant (i.e. active) cardiovascular disease:

    • Stroke, Transient ischemic attack (TIA) or myocardial infarction within ≤ 6 months prior to day 1.
    • Unstable angina or NYHA Grade II or greater congestive heart failure (CHF).
    • Serious cardiac arrhythmia requiring medication.
  9. Mental status, symptomatic epilepsy or other CNS disease where the investigator assesses the patient not fit for the clinical study.
  10. Other medications or conditions that in the Investigator's opinion would contraindicate study participation of safety reasons or interfere with the interpretation of study results. Other severe medical conditions, including serious heart disease, unstable diabetes, uncontrolled hypercalcemia or previous organ transplants. Participation in another clinical trial with experimental medication within 30 days prior to registration.
  11. Known hypersensitivity to gemcitabine and/or nab-paclitaxel.
  12. Pregnant women or women who are breastfeeding.
  13. Prior or present neuropathy > grade I (NCI-CTCAE v.5.0).
  14. Curatively intended treatment.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Peter M Vestlev, MD +4522779696 pmv@scandiononcology.com
Listed Location Countries  ICMJE Denmark,   Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04652206
Other Study ID Numbers  ICMJE SCO101-002
2020-002627-11 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Scandion Oncology A/S
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Scandion Oncology A/S
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Alcedis GmbH
Investigators  ICMJE Not Provided
PRS Account Scandion Oncology A/S
Verification Date December 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP